March 2 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS TO EXPAND PIPELINE WITH ACQUISITION OF IPN-1087, A SMALL MOLECULE TARGETING NTSR1, FROM IPSEN
* FUSION PHARMACEUTICALS - INTENDS TO USE IPN-1087 TO CREATE ALPHA-EMITTING RADIOPHARMACEUTICAL, FPI-2059, TARGETING SOLID TUMORS EXPRESSING NTSR1
* FUSION PHARMACEUTICALS INC - FUSION WILL ISSUE TO IPSEN 400,000 SHARES OF COMMON STOCK UPON CLOSING
* FUSION PHARMACEUTICALS INC - FUSION WILL ISSUE ADDITIONAL 200,000 SHARES UPON ACHIEVEMENT OF PATENT-RELATED MILESTONE
* FUSION PHARMACEUTICALS INC - WILL ALSO BE OBLIGATED TO PAY UP TO AN ADDITIONAL EUR 67.5 MILLION UPON ACHIEVEMENT OF SOME MILESTONES
* FUSION PHARMACEUTICALS INC - DEAL INCLUDES PAYMENT OF UP TO EUR 350.0 MILLION IN NET SALES MILESTONES